Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT8V9G)

Drug Name

R1295 Drug Info

Synonyms

CHEMBL2146615

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Discontinued in Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-4/beta-7 (ITGA4/B7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MLN0002	DMP2LZ8	Crohn disease	DD70	Approved	[3]
TRK-170	DM13G5R	Inflammatory bowel disease	DD72	Phase 2	[4]
PN-943	DMUZLKW	Ulcerative colitis	DD71	Phase 2	[5]
MORF-057	DMS274E	Crohn disease	DD70	Phase 2	[6]
GS-1427	DMDDBG1	Inflammation	1A00-CA43.1	Phase 1	[7]
TR-14035	DMWD39E	Multiple sclerosis	8A40	Discontinued in Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
2	Vedolizumab: an 47 integrin inhibitor for inflammatory bowel diseases.Ann Pharmacother.2014 Dec;48(12):1629-35.
3	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5	Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of alpha4beta7, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1263-1278.
6	ClinicalTrials.gov (NCT05291689) A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1). U.S.National Institutes of Health.
7	Clinical pipeline report, company report or official report of Gilead
8	Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89.